<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Einstein (Sao Paulo)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Einstein (Sao Paulo)</journal-id>
      <journal-id journal-id-type="publisher-id">eins</journal-id>
      <journal-title-group>
        <journal-title>Einstein</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1679-4508</issn>
      <issn pub-type="epub">2317-6385</issn>
      <publisher>
        <publisher-name>Instituto Israelita de Ensino e Pesquisa Albert Einstein</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26537508</article-id>
      <article-id pub-id-type="pmc">4878638</article-id>
      <article-id pub-id-type="publisher-id">S1679-45082015RC3013</article-id>
      <article-id pub-id-type="doi">10.1590/S1679-45082015RC3013</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Adult presentation of Bartter syndrome type IV with erythrocytosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Heilberg</surname>
            <given-names>Ita Pfeferman</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>T&#xF3;toli</surname>
            <given-names>Cl&#xE1;udia</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Calado</surname>
            <given-names>Joaquim Tomaz</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Universidade Federal de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brazil.</aff>
      <aff id="aff2"><label>2</label>Faculdade de Ci&#xEA;ncias M&#xE9;dicas, Universidade Nova de Lisboa, Lisboa, Portugal.</aff>
      <author-notes>
        <corresp id="c01"><label>Corresponding author</label>: Ita Pfeferman Heilberg &#x2013; Rua Botucatu, 740 &#x2013; Vila Clementino &#x2013; Zip code: 04023-900 &#x2013; S&#xE3;o Paulo, SP, Brazil &#x2013; Phone: (55 11) 5904-1697 &#x2013; E-mail: <email>ita.heilberg@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Oct-Dec</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Oct-Dec</season>
        <year>2015</year>
      </pub-date>
      <volume>13</volume>
      <issue>4</issue>
      <fpage>604</fpage>
      <lpage>606</lpage>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>10</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>8</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>Abstract</title>
        <p>Bartter syndrome comprises a group of rare autosomal-recessive salt-losing disorders with distinct phenotypes, but one unifying pathophysiology consisting of severe reductions of sodium reabsorption caused by mutations in five genes expressed in the thick ascending limb of Henle, coupled with increased urinary excretion of potassium and hydrogen, which leads to hypokalemic alkalosis. Bartter syndrome type IV, caused by loss-of-function mutations in barttin, a subunit of chloride channel CLC-Kb expressed in the kidney and inner ear, usually occurs in the antenatal-neonatal period. We report an unusual case of late onset presentation of Bartter syndrome IV and mild phenotype in a 20 years-old man who had hypokalemia, deafness, secondary hyperparathyroidism and erythrocytosis.</p>
      </abstract>
      <kwd-group>
        <kwd>Bartter syndrome</kwd>
        <kwd>Hypokalemia</kwd>
        <kwd>Chloride channels</kwd>
        <kwd>Case reports</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="13"/>
        <page-count count="3"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Antenatal Bartter syndrome (BS) type IV is characterized by polyhydramnios, premature birth, sensorineural deafness, severe salt and water loss, in the perinatal period, hypokalemic alkalosis, fever, vomiting, diarrhea, failure to thrive and chronic renal failure developing during infancy.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup> Late-onset presentation of BS with sensorineural deafness caused by a mutation of barttin has already been described in Japan,<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup> Portugal<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup> and Spain<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup> but to the best of our knowledge, this is the first case described in Brazil.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A deaf male patient was referred to the Nephrology unit for the first time at the age of 20 years due to asthenia and severe hypokalemia (potassium &#x2212; K of 2.0mEq/L; normal range: 3.5 to 5.0mEq/L), accompanied by erythrocytosis (hemoglobin &#x2212; Hb of 18.7g/dL; normal range: 12 to 15.5g/dL) detected at preoperative tests preceding a knee operation. The patient was the tenth child of consanguineous parents, who born premature by cesarean-section delivery after a complicated pregnancy by polyhydramnios. The patient had other deaf brother and a stone-forming sister. His parents noticed the severe hypoacusia on his second year of life. Upon admission, the patient was normotensive (110/70mmHg), had serum creatinine of 0.9mg/dL (normal range: 0.6 to 1.2mg/dL), weight of 54kg and 1.50m height (below the fifth percentile stature for age). Intravenous potassium chloride (KCI) replacement was started with 19.1% 20mL, followed by oral KCI supplementation 6.0% 20mL t.i.d. Additional serum laboratorial determinations showed a serum bicarbonate of 23.0mmoL/L, slightly decreased serum ionized calcium (1.09mmoL/L; normal range: 1.15 to 1.32mmoL/L), low serum phosphate (2.2mg/dL; normal range: 2.5 to 4.5mg/dL) and reduced fractional tubular reabsorption of phosphate (TRP; 74.1%; normal: &gt;80%) and high serum intact parathyroid hormone (PTH; 120ng/L; normal range: 15 to 68ng/L). Serum 25OH - vitamin D (28.2ng/mL) was slightly below the normal ranges (&gt;30ng/mL). Plasma renin (65.0ng/mL; upper limit &lt;6.0ng/mL) and aldosterone (55.7ng/dL; upper limit &lt;31ng/dL) were increased. His urinary volume was 3,530mL/day but hypercalciuria was not detected. A computed helical tomography excluded nephrocalcinosis. Urinary retinol-binding protein (RBP; 41mg/L; upper limit &lt;0.40mg/L) was markedly elevated. The etiology of erythrocytosis was investigated. Leucocytes and platelet counts were normal (and the bone marrow biopsy was mildly hypocellular except for an erythroid hyperplasia). Serum iron, ferritin and transferrin were normal. Erythropoietin (EPO) was also within normal limits (19.2mUI/mL). Oxyhemoglobin dissociation curve (P50) was normal and Janus kinase 2 (JAK-2) mutation analysis was negative, ruling out polycythemia vera. Two weeks after hospital discharge, spironolactone (100mg/day) was added to the oral KCI supplementation (30mEq/day). During follow-up the spironolactone dose was increased to 200mg/day for a better control of hypokalemia.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Although the finding of mild hypophosphatemia and elevated serum intact PTH could have initially suggested the presence of some disorder of phosphate metabolism in the present case, the association of hypokalemia and hearing impairment, even in the absence of metabolic alkalosis, led us to hypothesize about a late onset presentation of BS type IV. The diagnosis was confirmed by molecular analysis disclosing a c.139G&gt;A allele for the BSND gene in homozygosity, resulting in glycine (Gly) to arginine (Arg) at position 47 (p.G47R).</p>
      <p>As pointed out by Brum et al.,<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup> it is possible that the co-expression of p.G47R barttin and CLC-Ka may result in a less severe reduction of chloride currents, as seen in missense mutations, enabling barttin to retain some residual function with CLC-Kb, conditioning a milder phenotype.<sup>(<xref rid="B5" ref-type="bibr">5</xref>)</sup> Indeed, in a recent functional study, Janssen et al.<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup> have shown that the G47R was the only missense mutation tested that did not prevent the insertion of barttin into the surface membrane nor the activation of CLC-Kb/barttin channels, but that it impairs expression levels and complex glycosylation of the CLC-Kb channel so that its binding by barttin turns to be less effective. Therefore, distinct mutations of BSND cause phenotypes of varying severity.</p>
      <p>In the present case, renal function was preserved, like in all other described patients carrying this mutation. The absence of metabolic alkalosis in the current patient although unexpected, has already been described in cases of BS type I or II<sup>(<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>) </sup>or even in other adult onset presentations of BS type IV.<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup>
</p>
      <p>The most intriguing feature of the present case was the presence of a marked erythrocitosis in a non-smoking patient, in the absence of polycythemia vera, JAK-2 mutations or other causes of primary polycythemia. One case of Bartter associated with erythrocytosis had already been described in the literature in 1973 by Erkelens,<sup>(<xref rid="B9" ref-type="bibr">9</xref>)</sup> who hypothesized that the observed elevated erythropoietc activity of the serum could have resulted from juxtaglomerular hyperplasia leading to overproduction of both renin and EPO. However, the major source of EPO synthesis in the kidney is presently known to be the interstitial fibroblasts and not the juxtaglomerular apparatus. Besides, EPO levels showed to be within normal range in the present case. Although the erytrocitosis might have been secondary to polyuria, the 24 hours urine volume of the current patient was not so high to cause volume contraction. Therefore, the exact cause of erytrocytosis remains unclear.</p>
      <p>Increased levels of serum PTH could have been ascribed to mild hypocalcemia but not to hypomagnesemia, which was not observed in the present case. Pseudohypoparathyroidism (PHP) has been reported in patients with BS.<sup>(<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>)</sup> However, the observed low levels of serum phosphate, due to a reduced TRP do not suggest PHP. These findings are in agreement with Vaisbich et al.,<sup>(<xref rid="B12" ref-type="bibr">12</xref>)</sup> who also reported hypophosphatemia in 5 out of 12 BS cases. Finally, after a 2-month course of oral cholecalciferol supplementation (50,000UI), PTH levels normalized, suggesting that high PTH might have been secondary to the mild hypocalcemia and sub-normal levels of 25OH - vitamin D.</p>
      <p>In addition to phosphaturia, another evidence of proximal tubular dysfunction in the current case was the increased level of urinary RBP, a low molecular weight protein. Although the etiology of such dysfunction cannot be fully understood, other case has already been reported in the literature consisting of an adult onset Fanconi syndrome with kidney medullary cystic disease, non-specific aminoaciduria, lysozymuria and beta2-microglobulinuria, hyperreninemia and polycythemia with elevated serum EPO levels resembling Bartter&#x2019;s syndrome.<sup>(<xref rid="B13" ref-type="bibr">13</xref>)</sup> Another characteristic phenotype usually described in BS cases is the hypercalciuria, associated or not to nephrocalcinosis. Our patient did not show this phenotype, which agrees with other reports<sup>(<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>)</sup> possibly because of the low serum ionized calcium that led to a lower filtered load of calcium.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>CONCLUSION</title>
      <p>Molecular diagnosis is significant for a better understanding of the pathophysiology and approach to treatment of renal tubular disorders such as Bartter due to the phenotypic heterogeneity seen in this syndrome.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Birkenh&#xE4;ger</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Otto</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sch&#xFC;rmann</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Vollmer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ruf</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Maier-Lutz</surname>
              <given-names>I</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure</article-title>
          <source>Nat Genet</source>
          <year>2001</year>
          <volume>29</volume>
          <issue>3</issue>
          <fpage>310</fpage>
          <lpage>314</lpage>
          <pub-id pub-id-type="pmid">11687798</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miyamura</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Taguchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tokunaga</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nishikawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nishida</surname>
              <given-names>K</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Atypical Bartter syndrome with sensorineural deafness with G47R mutation of the beta-subunit for ClC-Ka and ClC-Kb chloride channels, barttin</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2003</year>
          <volume>88</volume>
          <issue>2</issue>
          <fpage>781</fpage>
          <lpage>786</lpage>
          <pub-id pub-id-type="pmid">12574213</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brum</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rueff</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Calado</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Unusual adult-onset manifestation of an attenuated Bartter&#xB4;s syndrome type IV renal phenotype caused by a mutation in BSND</article-title>
          <source>Nephrol Dial Transplant</source>
          <year>2007</year>
          <volume>22</volume>
          <issue>1</issue>
          <fpage>288</fpage>
          <lpage>289</lpage>
          <pub-id pub-id-type="pmid">16935888</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garc&#xED;a-Nieto</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Flores</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Luis-Yanes</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Gallego</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Villar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Claverie-Mart&#xED;n</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Mutation G47R in the BSND gene causes Bartter syndrome with deafness in two Spanish families</article-title>
          <source>Pediatr Nephrol</source>
          <year>2006</year>
          <volume>21</volume>
          <issue>5</issue>
          <fpage>643</fpage>
          <lpage>648</lpage>
          <pub-id pub-id-type="pmid">16572343</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Est&#xE9;vez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Boettger</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Birkenh&#xE4;ger</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Otto</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hildebrandt</surname>
              <given-names>F</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Barttin is a Cl- channel beta-subunit crucial for renal Cl- reabsorption and inner ear K+ secretion</article-title>
          <source>Nature</source>
          <year>2001</year>
          <volume>414</volume>
          <issue>6863</issue>
          <fpage>558</fpage>
          <lpage>561</lpage>
          <pub-id pub-id-type="pmid">11734858</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Janssen</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Scholl</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Domeyer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nothmann</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Leinenweber</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fahlke</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Disease-causing disfunctions of Barttin in Bartter Syndrome type IV</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2009</year>
          <volume>20</volume>
          <issue>1</issue>
          <fpage>145</fpage>
          <lpage>153</lpage>
          <pub-id pub-id-type="pmid">18776122</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berttinelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ciarmatori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cesareo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tedeschi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ruffla</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Appiani</surname>
              <given-names>AC</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Phenotypic variability in Bartter syndrome type I</article-title>
          <source>Pediatr Nephrol</source>
          <year>2000</year>
          <volume>14</volume>
          <issue>10-11</issue>
          <fpage>940</fpage>
          <lpage>945</lpage>
          <pub-id pub-id-type="pmid">10975303</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nozu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>XJ</given-names>
            </name>
            <name>
              <surname>Kaito</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kanda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yokoyama</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Przybyslaw Krol</surname>
              <given-names>R</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>A novel mutation in KCNJ1 in a Bartter syndrome case diagnosed as pseudohypoaldosteronism</article-title>
          <source>Pediatric Nephrol</source>
          <year>2007</year>
          <volume>22</volume>
          <issue>8</issue>
          <fpage>1219</fpage>
          <lpage>1223</lpage>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Erkelens</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Statius</surname>
              <given-names>van Eps LW</given-names>
            </name>
          </person-group>
          <article-title>Bartter&#x2019;s syndrome and erythrocytosis</article-title>
          <source>Am J Med</source>
          <year>1973</year>
          <volume>55</volume>
          <issue>5</issue>
          <fpage>711</fpage>
          <lpage>719</lpage>
          <pub-id pub-id-type="pmid">4356102</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bando</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Miyakoshi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nagaoka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ohsawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>A case of pseudohypoparathyroidism (PHP) type II associated with Bartter&#x2019;s syndromerestoration of phosphaturic response to parathyroid hormone (PTH) by treatment for hypopotassemia</article-title>
          <source>Nihon Naibunpi Gakkai Zasshi</source>
          <year>1992</year>
          <volume>68</volume>
          <issue>7</issue>
          <fpage>676</fpage>
          <lpage>687</lpage>
          <comment>Japonese</comment>
          <pub-id pub-id-type="pmid">1516722</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iba</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Morii</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yasumoto</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kishimoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mitsuhashi</surname>
              <given-names>T</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>A case report of pseudohypoparathyroidism (Drezner&#x2019;s type I) associated with probable Bartter&#x2019;s syndrome</article-title>
          <source>Endocrinol Jpn</source>
          <year>1981</year>
          <volume>28</volume>
          <issue>5</issue>
          <fpage>595</fpage>
          <lpage>604</lpage>
          <comment>Japanese</comment>
          <pub-id pub-id-type="pmid">7047153</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vaisbich</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Fujimura</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>VH</given-names>
            </name>
          </person-group>
          <article-title>Bartter syndrome: benefits and side effects of long-term treatment</article-title>
          <source>Pediatr Nephrol</source>
          <year>2004</year>
          <volume>19</volume>
          <issue>8</issue>
          <fpage>858</fpage>
          <lpage>863</lpage>
          <pub-id pub-id-type="pmid">15206026</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fyhrquist</surname>
              <given-names>FY</given-names>
            </name>
            <name>
              <surname>Klockars</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gordin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>T&#xF6;rnroth</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kock</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Hyperreninemia, lysozymuria, and erythrocytosis in Fanconi syndrome with medullary cystic kidney</article-title>
          <source>Acta Med Scand</source>
          <year>1980</year>
          <volume>207</volume>
          <issue>5</issue>
          <fpage>359</fpage>
          <lpage>365</lpage>
          <pub-id pub-id-type="pmid">6992516</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="TRpt" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Apresenta&#xE7;&#xE3;o tardia de s&#xED;ndrome de Bartter tipo IV com eritrocitose</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Heilberg</surname>
            <given-names>Ita Pfeferman</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>T&#xF3;toli</surname>
            <given-names>Cl&#xE1;udia</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Calado</surname>
            <given-names>Joaquim Tomaz</given-names>
          </name>
          <xref ref-type="aff" rid="aff2002">
<sup>2</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1002"><label>1</label> Universidade Federal de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brasil.</aff>
      <aff id="aff2002"><label>2</label> Faculdade de Ci&#xEA;ncias M&#xE9;dicas, Universidade Nova de Lisboa, Lisboa, Portugal.</aff>
      <author-notes>
        <corresp id="c01002"> Autor correspondente: Ita Pfeferman Heilberg &#x2013; Rua Botucatu, 740 &#x2013; Vila Clementino &#x2013; CEP: 04023-900 &#x2013; S&#xE3;o Paulo, SP, Brasil &#x2013; Tel.: (11) 5904-1697 &#x2013; E-mail: ita.heilberg@gmail.com </corresp>
      </author-notes>
      <abstract>
        <title>Resumo</title>
        <p>A s&#xED;ndrome de Bartter compreende um grupo raro de doen&#xE7;as autoss&#xF4;micas recessivas perdedoras de sal, decorrentes de muta&#xE7;&#xF5;es em genes expressos na por&#xE7;&#xE3;o ascendente espessa da al&#xE7;a de Henle, com fen&#xF3;tipos distintos, por&#xE9;m fisiopatogenia &#xFA;nica, que consiste em redu&#xE7;&#xE3;o severa da reabsor&#xE7;&#xE3;o de s&#xF3;dio, e aumento da excre&#xE7;&#xE3;o urin&#xE1;ria de hidrog&#xEA;nio e pot&#xE1;ssio, levando &#xE0; alcalose hipocal&#xEA;mica. A s&#xED;ndrome de Bartter tipo IV, causada por muta&#xE7;&#xF5;es com perda de fun&#xE7;&#xE3;o da bartina, uma subunidade do canal de cloro CLC-Kb expressa no rim e ouvido interno, geralmente se apresenta nos per&#xED;odos ante e neonatal. No presente relato, descreve-se um caso n&#xE3;o usual de s&#xED;ndrome de Bartter tipo IV com apresenta&#xE7;&#xE3;o tardia e fen&#xF3;tipo atenuado, diagnosticado por an&#xE1;lise molecular, em um homem adulto de 20 anos que se apresentava com hipocalemia, surdez, hiperparatireoidismo secund&#xE1;rio e eritrocitose.</p>
      </abstract>
      <kwd-group>
        <kwd>S&#xED;ndrome de Bartter</kwd>
        <kwd>Hipopotassemia</kwd>
        <kwd>Canais de cloreto</kwd>
        <kwd>Relatos de casos</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec>
        <title>INTRODU&#xC7;&#xC3;O</title>
        <p>A s&#xED;ndrome de Bartter (SB) antenatal tipo IV &#xE9; caracterizada por polihidr&#xE2;mnio, nascimento prematuro, <italic>d&#xE9;ficit</italic> auditivo sens&#xF3;rio-neural e perda severa de sal e &#xE1;gua no per&#xED;odo perinatal, alcalose hipocal&#xEA;mica, febre, v&#xF4;mito, diarreia, <italic>d&#xE9;ficit</italic> de crescimento e desenvolvimento de insufici&#xEA;ncia renal cr&#xF4;nica na inf&#xE2;ncia.<sup>(<xref rid="B1" ref-type="bibr">1</xref>) </sup>A apresenta&#xE7;&#xE3;o de SB de in&#xED;cio tardio com perda auditiva sens&#xF3;rio-neural causada por muta&#xE7;&#xE3;o no gene da bartina j&#xE1; foi descrita no Jap&#xE3;o,<sup>(<xref rid="B2" ref-type="bibr">2</xref>) </sup>em Portugal<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup> e na Espanha,<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup> mas trata-se do primeiro caso descrito no Brasil.</p>
      </sec>
      <sec>
        <title>RELATO DE CASO</title>
        <p>Paciente surdo, do sexo masculino, foi encaminhado para a enfermaria de Nefrologia pela primeira vez aos 20 anos de idade devido a quadro de astenia e hipocalemia aguda (pot&#xE1;ssio &#x2212; K s&#xE9;rico de 2,0mEq/L; valor normal de 3,5 a 5,0mEq/L), acompanhados de eritrocitose (hemoglobina &#x2212; Hb de 18,7g/dL; valor normal de 12 a 15,5g/dL) detectados em exame pr&#xE9;-operat&#xF3;rios anteriores a uma cirurgia de joelho. Tratava-se do d&#xE9;cimo filho de pais consangu&#xED;neos, que nasceu prematuro de parto ces&#xE1;rea, ap&#xF3;s gesta&#xE7;&#xE3;o complicada por polihidr&#xE2;mnio. O paciente apresentava um outro irm&#xE3;o com surdez e uma irm&#xE3; com c&#xE1;lculo renal. Seus pais notaram sua hipoacusia no segundo ano de vida. Na interna&#xE7;&#xE3;o, o paciente apresentava-se normotenso (110/70mmHg), com creatinina s&#xE9;rica de 0,9mg/dL (valor normal de 0,6 a 1,2mg/dL), peso de 54kg e altura de 1,50m (abaixo do percentil 5 de estatura para idade). Iniciou-se reposi&#xE7;&#xE3;o intravenosa com cloreto pot&#xE1;ssio (KCI) 19,1% 20mL intravenoso, seguido por suplementa&#xE7;&#xE3;o de KCI via oral 6,0% 20mL tr&#xEA;s vezes ao dia. Al&#xE9;m disso, as determina&#xE7;&#xF5;es laboratoriais s&#xE9;ricas mostraram bicarbonato s&#xE9;rico de 23,0mmoL/L, redu&#xE7;&#xE3;o discreta de c&#xE1;lcio s&#xE9;rico ionizado (1,09mmoL/L; valor normal de 1,15 a 1,32mmoL/L), fosfato s&#xE9;rico baixo (2,2mg/dL; valor normal de 2,5 a 4,5mg/dL), redu&#xE7;&#xE3;o da reabsor&#xE7;&#xE3;o tubular fracional de f&#xF3;sforo (TRP - <italic>tubularreabsorption of phosphate</italic>; 74,1%; normal acima de 80%) e paratorm&#xF4;nio (PTH) intacto elevado (120ng/L; valor normal de 15 a 68ng/L). Os n&#xED;veis s&#xE9;ricos de 25OH-vitamina D (28,2ng/mL) estavam discretamente abaixo do normal (&gt;30ng/mL). Foram observadas eleva&#xE7;&#xF5;es na renina plasm&#xE1;tica (65,0ng/mL; limite normal &lt;6,0ng/mL) e aldosterona (55,7ng/dL; limite normal &lt;31ng/dL). O volume urin&#xE1;rio do paciente era de 3.530mL/dia, por&#xE9;m n&#xE3;o foi detectada hipercalciuria. Excluiu-se nefrocalcinose, por meio de tomografia computadorizada helicoidal. A prote&#xED;na ligadora de retinol (RBP - <italic>retinol-binding protein</italic>) (41mg/L; limite normal &lt;0,40mg/L) mostrou-se significativamente elevada. A etiologia dos eritrocitose tamb&#xE9;m foi investigada. A contagem de plaquetas e leuc&#xF3;citos encontrava-se normal (bi&#xF3;psia da medula &#xF3;ssea revelou-se discretamente hipocelular com exce&#xE7;&#xE3;o da hiperplasia eritroide). Ferro s&#xE9;rico, ferritina e transferrina, bem como eritropoietina (EPO), encontravam-se dentro dos limites de normalidade (19,2mUl/mL). A curva de dissocia&#xE7;&#xE3;o da oxihemoglobina (P50) estava normal, e a an&#xE1;lise para muta&#xE7;&#xE3;o da Janus-quinase 2 (JAK-2) foi negativa, sendo descartada policitemia vera. Na alta hospitalar ap&#xF3;s 2 semanas, foi prescrita espironolactona (100mg/dia), al&#xE9;m da suplementa&#xE7;&#xE3;o com KCI por via oral (30mEq/dia). No seguimento, a dose de espironolactona foi aumentada para 200mg/dia, para melhor controle da hipocalemia.</p>
      </sec>
      <sec>
        <title>DISCUSS&#xC3;O</title>
        <p>No presente caso, apesar de os achados de hipofosfatemia leve com PTH intacto elevado poderem ter sugerido inicialmente a presen&#xE7;a de algum dist&#xFA;rbio do metabolismo de f&#xF3;sforo, a associa&#xE7;&#xE3;o de hipocalemia e defici&#xEA;ncia auditiva, mesmo na aus&#xEA;ncia de alcalose metab&#xF3;lica, levou &#xE0; hip&#xF3;tese de SB tipo IV com in&#xED;cio tardio. O diagn&#xF3;stico foi confirmado por meio de an&#xE1;lise molecular, que revelou um alelo c.139G&gt;A para o gene BSND em homozigose, resultando na troca de glicina (Gly) para arginina (Arg) na posi&#xE7;&#xE3;o 47 (p.G47R).</p>
        <p>Conforme descrito por Brum et al.,<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup> &#xE9; poss&#xED;vel que a coexpress&#xE3;o do p.G47R de bartina, com os canais CLC-Ka, tenha resultado em uma redu&#xE7;&#xE3;o menos severa das correntes de cloro, como observado em muta&#xE7;&#xF5;es <italic>missense</italic>, possibilitando que a bartina retivesse algumas fun&#xE7;&#xF5;es residuais, como CLC-Kb, condicionando um fen&#xF3;tipo menos severo.<sup>(<xref rid="B5" ref-type="bibr">5</xref>)</sup> No entanto, em um estudo funcional recente, Janssen et al.<sup>(<xref rid="B6" ref-type="bibr">6</xref>) </sup>demonstraram que a G47R foi a &#xFA;nica muta&#xE7;&#xE3;o <italic>missense</italic> examinada que n&#xE3;o preveniu a inser&#xE7;&#xE3;o da bartina na superf&#xED;cie da membrana, nem a ativa&#xE7;&#xE3;o dos canais CLC-Kb/bartina, por&#xE9;m tal muta&#xE7;&#xE3;o alterou os n&#xED;veis de glicosila&#xE7;&#xE3;o dos canais CLC-Kb, de forma que sua liga&#xE7;&#xE3;o por meio de bartina se tornasse menos efetiva. Portanto, muta&#xE7;&#xF5;es distintas na bartina causam fen&#xF3;tipos com diferentes n&#xED;veis de severidade.</p>
        <p>Neste caso, a fun&#xE7;&#xE3;o renal do paciente estava preservada, corroborando todos os casos descritos na literatura de pacientes com a mesma muta&#xE7;&#xE3;o. A aus&#xEA;ncia de alcalose metab&#xF3;lica em nosso paciente, apesar de inesperada, j&#xE1; foi descrita em casos de SB tipos I e II,<sup>(<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>) </sup>e at&#xE9; nos primeiros sintomas da SB tipo IV em adultos.<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup>
</p>
        <p>A caracter&#xED;stica mais intrigante de nosso caso foi a presen&#xE7;a de uma marcada eritrocitose (poliglobulia) em um paciente n&#xE3;o fumante, na aus&#xEA;ncia de policitemia vera, muta&#xE7;&#xF5;es na JAK-2 ou de outras causas de policitemia prim&#xE1;ria. Um caso de Bartter associado com eritrocitose j&#xE1; foi descrito na literatura em 1973 por Erkelens,<sup>(<xref rid="B9" ref-type="bibr">9</xref>)</sup> que sup&#xF4;s que a elevada atividade eritropoi&#xE9;tica no soro poderia ter resultado de uma hiperplasia juxtaglomerular<italic>,</italic> levando &#xE0; produ&#xE7;&#xE3;o excessiva tanto de renina quanto de EPO. Por&#xE9;m considera-se atualmente que a maior fonte de s&#xED;ntese de EPO no rim sejam os fibroblastos intersticiais, e n&#xE3;o o aparelho juxtaglomerular. Al&#xE9;m disso, no presente caso, os n&#xED;veis s&#xE9;ricos de EPO encontravam-se dentro dos limites da normalidade. Apesar de a eritrocitose poder ter sido secund&#xE1;ria &#xE0; poli&#xFA;ria, o volume de urina de 24 horas nesse paciente n&#xE3;o estava elevado a ponto de causar uma contra&#xE7;&#xE3;o de volume. Assim, a causa exata da eritrocitose permanece desconhecida.</p>
        <p>Os n&#xED;veis elevados de PTH poderiam ser atribu&#xED;dos &#xE0; hipocalcemia leve, mas n&#xE3;o &#xE0; hipomagnesemia, n&#xE3;o observada no presente caso. Associa&#xE7;&#xE3;o com pseudo-hipoparatireoidismo (PHP) tem sido relatada em pacientes com SB.<sup>(<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>)</sup> Por&#xE9;m, os n&#xED;veis baixos de fosfato s&#xE9;rico observados, devido &#xE0; reduzida reabsor&#xE7;&#xE3;o tubular, n&#xE3;o sugerem PHP. Esses achados corroboram os de Vaisbich et al.,<sup>(<xref rid="B12" ref-type="bibr">12</xref>)</sup> que tamb&#xE9;m relataram hipofosfatemia em 5 de 12 casos com SB. Por fim, ap&#xF3;s 2 meses de suplementa&#xE7;&#xE3;o com colecalciferol por via oral (50.000UI), os n&#xED;veis de PTH se normalizaram, sugerindo que o PTH elevado deve ter sido secund&#xE1;rio &#xE0; hipocalcemia leve e aos n&#xED;veis subnormais de 25OH-vitamina D.</p>
        <p>Al&#xE9;m da fosfat&#xFA;ria, outra evid&#xEA;ncia de disfun&#xE7;&#xE3;o tubular proximal no presente caso foi o aumento do n&#xED;vel urin&#xE1;rio de prote&#xED;na de baixo peso molecular, como a prote&#xED;na ligadora de retinol (RBP). Apesar da etiologia dessa disfun&#xE7;&#xE3;o n&#xE3;o estar completamente esclarecida, um outro caso de s&#xED;ndrome de Fanconi de in&#xED;cio na idade adulta, associado a doen&#xE7;a renal c&#xED;stica medular, aminoacid&#xFA;ria inespec&#xED;fica, lisozim&#xFA;ria, perda de beta2-microglobulina, hiperreninemia e policitemia, com n&#xED;veis elevados de eritropoetina s&#xE9;rica similares aos da SB, j&#xE1; foi descrito na literatura.<sup>(<xref rid="B13" ref-type="bibr">13</xref>)</sup> Outra caracter&#xED;stica fenot&#xED;pica geralmente descrita nos casos de SB &#xE9; a hipercalci&#xFA;ria, associada ou n&#xE3;o a nefrocalcinose, que n&#xE3;o foi detectada em nosso paciente, tamb&#xE9;m corroborando outros relatos,<sup>(<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>)</sup> possivelmente devido ao c&#xE1;lcio s&#xE9;rico reduzido, que leva a menor carga filtrada.</p>
      </sec>
      <sec>
        <title>CONCLUS&#xC3;O</title>
        <p>O diagn&#xF3;stico molecular foi importante para entender melhor a fisiopatogenia de dist&#xFA;rbios tubulares renais, tal como a s&#xED;ndrome de Bartter, em fun&#xE7;&#xE3;o da heterogeneidade fenot&#xED;pica presente nessa s&#xED;ndrome.</p>
      </sec>
    </body>
  </sub-article>
</article>
</pmc-articleset>
